To include your compound in the COVID-19 Resource Center, submit it here.

pSivida rises on Phase III uveitis data

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) gained $0.79 (21%) to $4.49 on NASDAQ on Tuesday after its Medidur fluocinolone

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE